Stress and substance use disorders remain two of the most highly prevalent psychiatric conditions and are often comorbid. While individually these conditions have a debilitating impact on the patient and a high cost to society, the symptomology and treatment outcomes are further exacerbated when they occur together. As such, there are few effective treatment options for these patients, and recent investigation has sought to determine the neural processes underlying the co-occurrence of these disorders to identify novel treatment targets. One such mechanism that has been linked to stress- and addiction-related conditions is neuroimmune signaling. Increases in inflammatory factors across the brain have been heavily implicated in the etiology of these disorders, and this review seeks to determine the nature of this relationship. According to the “dual-hit” hypothesis, also referred to as neuroimmune priming, prior exposure to either stress or drugs of abuse can sensitize the neuroimmune system to be hyperresponsive when exposed to these insults in the future. This review completes an examination of the literature surrounding stress-induced increases in inflammation across clinical and preclinical studies along with a summarization of the evidence regarding drug-induced alterations in inflammatory factors. These changes in neuroimmune profiles are also discussed within the context of their impact on the neural circuitry responsible for stress responsiveness and addictive behaviors. Further, this review explores the connection between neuroimmune signaling and susceptibility to these conditions and highlights the anti-inflammatory pharmacotherapies that may be used for the treatment of stress and substance use disorders.

substance use disorder

stress

neuroinflammatory priming

anti-inflamatory treatments

substance use disorders

post-traumatic stress disorder

hypothalamic-pituitary-adrenal axis

mitogen activated protein kinase

transforming growth factors

major depressive disorder

selective serotonin reuptake inhibitors

paraventricular nucleus of the hypothalamus

corticotropin releasing factor

anterior cingulate cortex

ventral tegmental area

adrenocorticotropic hormone

conditioned place preference

single nucleotide polymorphisms

© 2022 Elsevier Inc. All rights reserved.